Cobenfy Fails Phase 3 Adjunctive Schizophrenia Trial

Bristol Myers Squibb's schizophrenia drug, Cobenfy, failed to meet its primary and secondary endpoints in a six-week phase 3 trial as an adjunctive therapy for patients with inadequately controlled symptoms. The trial demonstrated only a modest 2.0-point reduction in symptom severity compared to placebo, which was not statistically significant. As a result, Cobenfy's potential as a supplemental therapy is now uncertain, with analysts noting diminished prospects for broader adoption. Some continued use is anticipated due to limited adjunctive treatment options. Cobenfy remains approved as a monotherapy for schizophrenia based on earlier successful trials. Bristol Myers Squibb plans a full evaluation and will present detailed results at an upcoming medical conference.